Koksoy Adem Yasin, Kurtul Meltem, Ozsahin Aslı Kantar, Cayci Fatma Semsa, Tayfun Meltem, Bayrakci Umut Selda
J Pediatr Pharmacol Ther. 2018 Nov-Dec;23(6):494-498. doi: 10.5863/1551-6776-23.6.494.
Hyponatremia is one of the most common electrolyte abnormalities encountered in the clinical setting in hospitalized patients. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the leading cause of hyponatremia in most of these cases. While fluid restriction, hypertonic saline infusion, diuretics, and the treatment of underlying conditions constitute the first line of treatment of SIADH, in refractory cases, and especially for pediatric patients, there seems not to be any other choice for treatment. Tolvaptan, although its use in pediatric patients is still very limited, might be an attractive treatment option for correction of hyponatremia due to SIADH. Here we present a pediatric case of SIADH that was resistant to treatment with fluid restriction and hypertonic saline infusion and was treated successfully with tolvaptan. Tolvaptan could be a good, safe, and effective treatment option in pediatric SIADH cases that are resistant to treatment. However, the dosage should be titrated carefully.
低钠血症是住院患者临床中最常见的电解质异常之一。抗利尿激素分泌不当综合征(SIADH)是大多数此类病例中低钠血症的主要原因。虽然液体限制、高渗盐水输注、利尿剂以及基础疾病的治疗构成了SIADH的一线治疗方法,但在难治性病例中,尤其是儿科患者,似乎没有其他治疗选择。托伐普坦虽然在儿科患者中的使用仍然非常有限,但可能是纠正SIADH所致低钠血症的一种有吸引力的治疗选择。在此我们报告一例SIADH儿科病例,该病例对液体限制和高渗盐水输注治疗耐药,而用托伐普坦成功治疗。在对治疗耐药的儿科SIADH病例中,托伐普坦可能是一种良好、安全且有效的治疗选择。然而,剂量应仔细滴定。